½ÃÀ庸°í¼­
»óǰÄÚµå
1496000

¼¼°èÀÇ º¥´õ Á߸³ ¾ÆÄ«À̺ê(NVA) ½ÃÀå - ¿¹Ãø(2024-2029³â)

Global Vendor Neutral Archive (VNA) Market - Forecasts from 2024 to 2029

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Knowledge Sourcing Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 124 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

º¥´õ Á߸³ ¾ÆÄ«À̺ê(VNA) ½ÃÀåÀº 2022³â 6¾ï 107¸¸ ´Þ·¯ ±Ô¸ð¿¡¼­ ¿¬Æò±Õ 7.42% ¼ºÀåÇÏ¿© 2029³â¿¡´Â 9¾ï 9,248¸¸ 1,000´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ·¯ÇÑ ¼ºÀåÀÇ ¹è°æ¿¡´Â ÀÇ·á ¿µ»ó ¾ÆÄ«ÀÌºê ½Ã½ºÅÛÀÇ º¸ÆíÈ­, µ¥ÀÌÅÍ ÀúÀå ºñ¿ë Àý°¨, ÀüÀÚÀǹ«±â·Ï »ê¾÷ÀÇ °íµµÀÇ ÅëÇÕ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±âÁ¸ µ¥ÀÌÅÍ ¾ÆÄ«ÀÌºê ½Ã½ºÅÛ°úÀÇ È£È¯¼ºÀ¸·Î ÀÎÇØ º¥´õ Á߸³ ¾ÆÄ«À̺갡 ¼±È£µÇ°í ÀÖ½À´Ï´Ù.

º¥´õ Á߸³ ¾ÆÄ«À̺ê(VNA)´Â ÀÇ·á ¿µ»óÀ» À§ÇÑ ±â¼úÀÔ´Ï´Ù. ÀÇ·á À̹ÌÁö¿Í ¹®¼­´Â Ç¥ÁØ ÀÎÅÍÆäÀ̽º¸¦ °®Ãá ÀûÀýÇÑ Ç¥ÁØÈ­µÈ Æ÷¸ËÀ¸·Î º¸°üµË´Ï´Ù. Ç¥ÁØÈ­µÇ¾î Àֱ⠶§¹®¿¡ ÀÌ·¯ÇÑ À̹ÌÁö´Â ´Ù¸¥ ¸ðµç ½Ã½ºÅÛ¿¡¼­ º¥´õ Á߸³ÀûÀÎ ¹æ½ÄÀ¸·Î Á¢±ÙÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ¿ë¾î´Â ±âÁ¸ÀÇ À̹ÌÁö ÀúÀå Åë½Å ½Ã½ºÅÛ¿¡¼­ »ç¿ëµÇ¾ú½À´Ï´Ù.

VNA¿Í À̹ÌÁö ¾ÆÄ«ÀÌºê ¹× Åë½Å ½Ã½ºÅÛÀº ¸¹Àº °øÅëÁ¡À» °¡Áö°í ÀÖÀ¸¸ç, VNA ½ÃÀåÀº Ç¥ÁØ ±â¹Ý ½ºÅ丮Áö, ÀçÇØº¹±¸, ¶óÀÌÇÁ»çÀÌŬ °ü¸® Àü·«, ¸¹Àº VNA ÁÖ¿ä ±â¾÷¿¡ À¯¸®ÇÑ Á¤ºÎ ±ÔÁ¦ µîÀÇ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ÃßÁ¤ ¹× ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ÃËÁø¿äÀÎ:

  • ÀüÀڰǰ­±â·Ï(EHR)ÀÇ Áõ°¡ Ãß¼¼´Â ½ÃÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÇöÀç ¾çÁúÀÇ ÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇϰí È¿À²ÀûÀÎ ÀÇ·á °ü¸®¸¦ À¯ÁöÇϱâ À§Çؼ­´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤ÀÌ ÇʼöÀûÀÔ´Ï´Ù. Áß¿äÇÑ ÀÇ»ç°áÁ¤À» À§Çؼ­´Â ȯÀÚÀÇ °Ç°­ °ü·Ã µ¥ÀÌÅ͸¦ È®º¸ÇØ¾ß ÇÕ´Ï´Ù. µ¥ÀÌÅÍ¿Í È¯ÀÚ Á¤º¸´Â ¸¹Àº ÀÇ·á ¼­ºñ½º Á¦°øÀÚÀÇ ´Ù¾çÇÑ ½Ã½ºÅÛ¿¡ Á¸ÀçÇÏÁö¸¸, Àǻ糪 ÀÓ»óÀǰ¡ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ´Â °ÍÀº ¾Æ´Õ´Ï´Ù.

´ëºÎºÐÀÇ °æ¿ì, ȯÀÚ µ¥ÀÌÅÍ´Â ºÎ¼­º° »çÀϷγª ÆÄÀÏ ½Ã½ºÅÛ¿¡¼­ °ü¸®µÇ°í ÀÖ½À´Ï´Ù. ÀÌ´Â °á±¹ ºÒ¿ÏÀüÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸®´Â °á°ú¸¦ ÃÊ·¡ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ »óȲ°ú ÀÇ»ç°áÁ¤À» ¹æÁöÇϱâ À§ÇØ ÀüÀÚÀǹ«±â·ÏÀº ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. º¥´õ Á߸³ ¾ÆÄ«À̺ê´Â ȯÀÚ Á¤º¸¸¦ ÀüÀÚÀǹ«±â·Ï ½Ã½ºÅÛ¿¡ ÅëÇÕÇÕ´Ï´Ù. À̸¦ ÅëÇØ ÀÇ»ç¿Í ÀÓ»óÀÇ´Â È¿°úÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ÀüÀÚÀǹ«±â·ÏÀÇ È帧Àº ÀÌ¹Ì ¿À·¡ÀüºÎÅÍ ½ÃÀ۵Ǿú½À´Ï´Ù.

Á¤ºÎ°¡ ´Ù¾çÇÑ ÇÁ·Î±×·¥À» ½ÃÇàÇÏ°í º¸±ÞÀ» °­È­ÇÏ´Â ÀÌ´Ï¼ÅÆ¼ºê¸¦ ÃëÇϸ鼭 Àü ¼¼°è ¼±Áø±¹°ú °³¹ßµµ»ó±¹ ¸ðµÎ¿¡¼­ ÀüÀÚÀǹ«±â·ÏÀÇ º¸±ÞÀÌ °¡¼ÓÈ­µÇ¾ú½À´Ï´Ù. ±×·¯³ª EHR ½Ã½ºÅÛÀº ¼±Áø±¹¿¡¼­ ¼±Áø ±â¼úÀÇ Á¶±â µµÀÔÀ¸·Î ÀÎÇØ ¼±Áø±¹¿¡¼­ ´õ ±¤¹üÀ§ÇÏ°Ô Ã¤Åõǰí ÀÖ½À´Ï´Ù. ÀüÀÚ ÀÇ·á ±â·ÏÀ» °íµµ·Î ÅëÇÕÇÑ ÀÇ·á ±â°üÀº ȯÀÚ Á¤º¸¸¦ °ø°³ÇÏ¿© ÀÇ»ç ¹× ±âŸ ÀÇ·á Àü¹®°¡°¡ ÇÊ¿äÇÒ ¶§ ¾ðÁ¦µçÁö »ç¿ëÇÒ ¼ö ÀÖµµ·Ï ÇÒ ¼ö ÀÖ½À´Ï´Ù.

VNA ½Ã½ºÅÛ°ú °øÅëµÈ Ư¡À» °¡Áø ¿µ»ó ÀúÀå ¹× Åë½Å ½Ã½ºÅÛµµ VNA ½ÃÀå°ú ÇÔ²² ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, VNA¿Í ¿µ»ó ¾ÆÄ«ÀÌºê ¹× Åë½Å ½Ã½ºÅÛ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¼±Áø±¹ÀÇ ¸¹Àº º´¿ø¿¡¼­ ÀÌ·¯ÇÑ ±â¼úÀ» äÅÃÇϰí ÀÖÀ¸¸ç, °³¹ßµµ»ó±¹¿¡¼­µµ ºñ½ÁÇÑ È®»êÀÌ ±â´ëµÇ°í ÀÖ½À´Ï´Ù. ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

VNA ½Ã½ºÅÛÀÇ ¼ºÀå¿¡ ±â¿©ÇÏ´Â ´Ù¸¥ ¿äÀÎÀ¸·Î´Â ÀÇ·á ºÎ¹®¿¡ ´ëÇÑ °ü½É Áõ°¡¿Í ÀÇ·á ÁöÃâ Áõ°¡¸¦ µé ¼ö ÀÖ½À´Ï´Ù. º¥´õ Á߸³ ¾ÆÄ«À̺ê´Â ÁÖ·Î ¹æ»ç¼±°ú¿¡¼­ »ç¿ëµË´Ï´Ù. ¶ÇÇÑ È¯ÀÚ µ¥ÀÌÅ͸¦ ±â·Ï ¹× ÀúÀåÇϱâ À§ÇØ ÃÊÀ½ÆÄ Áø´Ü Àåºñ¿Í MRI Àåºñ¿¡µµ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¾ïÁ¦¿äÀÎ:

  • ½Ã½ºÅÛÀÇ ³ôÀº ºñ¿ëÀÌ ½ÃÀå ¼ºÀåÀÇ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

º¥´õ Á߸³ ¾ÆÄ«À̺ê´Â Àå±âÀûÀÎ µ¥ÀÌÅ͸¦ Á¦°øÇÏÁö ¾Ê±â ¶§¹®¿¡ ¼ÒºñÀÚµéÀÌ ±âÇÇÇÏ´Â °æÇâÀÌ ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î, ÀÌ ¾ÆÄ«À̺ê Á¦Ç°Àº ¼ö¸í ÁֱⰡ ª°í ÀÚ¸³ÀûÀÌÁö ¾Ê½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ VNA ½ÃÀåÀÇ ¹ß¸ñÀ» Àâ´Â´Ù. ³ôÀº ºñ¿ë°ú ´ë·®ÀÇ µ¥ÀÌÅ͸¦ ÀúÀåÇÏ´Â ¼º´É¿¡ ´ëÇÑ ÀDZ¸½ÉÀ¸·Î ÀÎÇØ ¸¹Àº ½ÅÈï±¹¿¡¼­´Â º´¿ø¿¡ ÀÌ ±â¼úÀ» µµÀÔÇÏÁö ¾Ê°í ÀÖ½À´Ï´Ù.

ºÏ¹Ì°¡ Å« ½ÃÀå Á¡À¯À²À» Â÷Áö

ºÏ¹Ì´Â º¥´õ Á߸³ ¾ÆÄ«ÀÌºê ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È¿¡µµ ¼±µÎ¸¦ À¯ÁöÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¹Ì±¹, ij³ª´Ù µî ºÏ¹Ì ±¹°¡µéÀº ¼±Áø ±â¼úÀ» °¡Àå ¸ÕÀú µµÀÔÇÑ ±¹°¡µéÀÔ´Ï´Ù. ÀÌµé ±¹°¡´Â ´Ù¾çÇÑ Çõ½Å ±â¼úÀ» Àû¿ëÇÏ¿© ÀÇ·á ºñ¿ë Àý°¨¿¡ ¾ÕÀå¼­°í ÀÖ½À´Ï´Ù.

Á¤º¸ ½Ã½ºÅÛÀº ÀÌ·¯ÇÑ ºñ¿ëÀ» Àý°¨Çϰí Ä¡·á °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ´Â ÃæºÐÇÑ ´É·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. VNA ½Ã½ºÅÛÀÇ ÀÌ·¯ÇÑ ¸¹Àº ÀåÁ¡À» °í·ÁÇÏ¿© ºÏ¹Ì ±¹°¡µéÀº VNAÀÇ °³¹ß ¹× Ȱ¿ëÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ º¥´õ Á߸³ ¾ÆÄ«ÀÌºê ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ´õ ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÁÖ¿ä °³¹ß

  • 2023³â 3¿ù - ConcertAIÀÇ TeraReconÀº Avicenna.AI¿Í Á¦ÈÞÇÏ¿© ÀÚ»çÀÇ Eureka Clinical AI Ç÷§Æû¿¡¼­ ¿ì¹ßÀû Æó»öÀüÁõÀ» °¨ÁöÇÏ´Â CINA-iPE ¼Ö·ç¼ÇÀ» ¼Ò°³ÇÕ´Ï´Ù. Avicenna.AI´Â µö·¯´×À» ÅëÇØ CT ½ºÄµ À̹ÌÁö¸¦ ºÐ¼®Çϰí, CT À̹ÌÁö¿¡¼­ »ý¸íÀ» À§ÇùÇÏ´Â ÁúȯÀ» ½Äº°Çϰí Á¤·®È­Çϸç, TeraReconÀÇ Eureka Clinical AI Ç÷§ÆûÀº Ÿ»ç AI ¾Ë°í¸®Áò¿¡ °³¹æµÈ AI SaaS Ç÷§ÆûÀÔ´Ï´Ù. AI SaaS À̹ÌÁö ÇØ¼® ¹× ÀÓ»óÀû ÆÇ´Ü °­È­ ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â ¼±µµÀûÀÎ AI SaaS Ç÷§ÆûÀÔ´Ï´Ù. ÀÌ ¼¼°è ÆÄÆ®³Ê½ÊÀº »ý¸íÀ» À§ÇùÇÏ´Â Æó»öÀüÁõÀÇ Ã¼°èÀûÀÎ º¸°í¿Í Ä¡·á¸¦ °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.
  • 2022³â 11¿ù - ÀÇ·á ¿µ»ó °ü¸® ¼Ö·ç¼ÇÀÇ ¼¼°è ¸®´õÀÎ ÀÎÅÚ·¹ÀÌµå ¸ÞµðÄà ½Ã½ºÅÛÁî(Intelerad Medical Systems)´Â COVID-19 È®»ê°ú º¸¾È ¿ì·Á·Î ÀÎÇØ 2026³â±îÁö 768¾ï ´Þ·¯ ±Ô¸ðÀÇ Å¬¶ó¿ìµå µµÀÔÀÌ ÀÌ·ç¾îÁú °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¼úÀº Á¾ÇÕÀûÀÎ º¸¾È Á¶Ä¡, µ¥ÀÌÅÍ ÀÌÁßÈ­ ¹× ¹é¾÷À» Á¦°øÇÏ°í ¿ÂÇÁ·¹¹Ì½º ¼Ö·ç¼Ç¿¡ ºñÇØ ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÁÖ¿ä º´¿ø°ú ÀÇ·á ½Ã½ºÅÛÀº ´õ ³ªÀº Á¢±Ù¼º, ÀÇ·á µ¥ÀÌÅÍ °³¼± ¹× ´õ ³ªÀº ±â¾÷ À̹ÌÁö Àü·«À» À§ÇØ Å¬¶ó¿ìµå µµÀÔ¿¡ ÁýÁßÇϰí ÀÖÀ¸¸ç, ÀÎÅÚ·¹À̵åÀÇ Cloud-Native Disaster Recovery ¼Ö·ç¼ÇÀº ȯÀÚ À̹ÌÁöÀÇ ¾ÈÀüÇÏ°í ºÐ¸®µÈ ºÒº¯ÀÇ »çº»À» Á¦°øÇÕ´Ï´Ù. Cloud Long-Term Archive´Â ȯÀÚ °Ç°­ Á¤º¸ÀÇ ¾ÈÀü°ú Á¢±ÙÀ» º¸ÀåÇÕ´Ï´Ù.
  • 2022³â 4¿ù - ÈÄÁöÇʸ§ ÇコÄÉ¾î ¾Æ¸Þ¸®Ä«(Fujifilm Healthcare Americas Corporation)°¡ ¹Ì±¹ ±¹¹æºÎ·ÎºÎÅÍ ¹Ì ÇØ±º ¹× °ø±º ÀÇ·á ½Ã¼³ÀÇ µðÁöÅÐ ¿µ»ó ³×Æ®¿öÅ©ÀÇ ¿µ»ó ¾ÆÄ«ÀÌºê ¹× Åë½Å ½Ã½ºÅÛ(DIN-PACS) Ç¥ÁØÈ­¸¦ ¼öÁÖÇß½À´Ï´Ù. À̹ø ¼öÁÖ´Â ÈÄÁöÇʸ§ÀÌ 2017³â ±¹¹æºÎ ¹°·ùû°ú ü°áÇÑ DIN-PACS °è¾à¿¡ µû¸¥ °ÍÀÔ´Ï´Ù. ÈÄÁöÇʸ§ÀÇ Â÷¼¼´ë ¼­¹ö »çÀ̵å PACS ½Ã½ºÅÛÀÎ ½Ã³À½º PACS(Synapse PACS)´Â ¹æ»ç¼± ºÎ¼­¸¦ ³Ñ¾î Àü»çÀûÀ¸·Î ¾ÈÀüÇÑ ¿µ»ó ¹× º¸°í¿¡ ´ëÇÑ Á¢±ÙÀ» °¡´ÉÇÏ°Ô Çϰí, ±â¾÷ ÀüüÀÇ ¿µ»ó µ¥ÀÌÅ͸¦ ÅëÇÕÇÕ´Ï´Ù.
  • 2022³â 3¿ù - Çʸ³½º´Â Áø´Ü ¿öÅ©Ç÷ο츦 °£¼ÒÈ­Çϰí Áø´ÜÀÇ Áú°ú »ý»ê¼ºÀ» Çâ»ó½ÃŰ´Â 2D/3D ½ÉÃÊÀ½ÆÄ ¼Ö·ç¼ÇÀÎ Ultrasound Workspace¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº »ç¿ëÀÚ Ä£È­ÀûÀÎ ÀÎÅÍÆäÀ̽º¿Í AI ±â¹Ý ¿µ»ó ºÐ¼® ÅøÀ» ÅëÇØ º¸´Ù ºü¸¥ Á¤·®Àû ÃøÁ¤°ú °Ë»çÀÚ °£ Àϰü¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Çʸ³½º´Â 3D ½ÉÃÊÀ½ÆÄÀÇ ¹ßÀü¿¡ ±â¿©ÇØ ¿Â ÀÇ»çÀÇ ÀǰßÀ» ¹Ý¿µÇÏ¿© °³¹ßµÈ ¼ÒÇÁÆ®¿þ¾î·Î º¥´õ Á߸³ÀûÀÎ ¾ÖÇø®ÄÉÀ̼ǰú µ¥ÀÌÅÍ ¼Ò½º ±â´ÉÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº ¹ÎøÇÑ ±â¼ú Ç÷§Æû, ¼Ò±Ô¸ð¿¡¼­ ´ë±Ô¸ð Á¶Á÷¿¡ À̸£´Â À¯¿¬ÇÑ ¶óÀ̼±½Ì, Á¾ÇÕÀûÀÎ ¾ÖÇø®ÄÉÀÌ¼Ç Áö¿ø µîÀ» Ư¡À¸·Î ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

  • ½ÃÀå °³¿ä
  • ½ÃÀå Á¤ÀÇ
  • Á¶»ç ¹üÀ§
  • ½ÃÀå ¼¼ºÐÈ­
  • ÅëÈ­
  • °¡Á¤
  • ±âÁØ ¿¬µµ¿Í ¿¹Ãø ¿¬µµ ŸÀÓ¶óÀÎ
  • ÀÌÇØ°ü°èÀÚ¿¡ ´ëÇÑ ÁÖ¿ä ÀÌÁ¡

Á¦2Àå Á¶»ç ¹æ¹ý

  • Á¶»ç µðÀÚÀÎ
  • Á¶»ç °úÁ¤

Á¦3Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • Porter's Five Forces ºÐ¼®
  • ¾÷°è ¹ë·ùüÀÎ ºÐ¼®
  • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ

Á¦5Àå º¥´õ Á߸³ ¾ÆÄ«À̺ê(NVA) ¼¼°è ½ÃÀå : Á¦°ø À¯Çüº°

  • ¼Ò°³
  • ¿ÂÇÁ·¹¹Ì½º VNA
  • ÇÏÀ̺긮µå VNA
  • Ç® Ŭ¶ó¿ìµå È£½ºÆ®Çü VNA

Á¦6Àå º¥´õ Á߸³ ¾ÆÄ«À̺ê(NVA) ¼¼°è ½ÃÀå : ¸ðµ¨º°

  • ¼Ò°³
  • ºÎ¹®Çü VNA
  • ¸ÖƼ ºÎ¹®Çü VNA
  • ¸ÖƼ »çÀÌÆ® VNA

Á¦7Àå º¥´õ Á߸³ ¾ÆÄ«À̺ê(NVA) ¼¼°è ½ÃÀå : Áö¿ªº°

  • ¼Ò°³
  • ºÏ¹Ì
  • ³²¹Ì
  • À¯·´
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ¾Æ½Ã¾ÆÅÂÆò¾ç

Á¦8Àå °æÀï ȯ°æ°ú ºÐ¼®

  • ÁÖ¿ä ±â¾÷°ú Àü·« ºÐ¼®
  • ½ÃÀå Á¡À¯À² ºÐ¼®
  • ÇÕº´, Àμö, ÇÕÀÇ¿Í Çù¾÷
  • °æÀï ´ë½Ãº¸µå

Á¦9Àå ±â¾÷ °³¿ä

  • Afga healthcare
  • FUJIFILM Holding Corporation
  • Dell Technologies Inc
  • GE Healthcare
  • IBM Corporation
  • Koninklijke Philips NV
  • Lexmark International Inc
  • McKesson Corporation
  • Novarad Corporation
  • Siemen AG
ksm 24.06.24

The vendor-neutral archive (VNA) market is projected to grow at a compound annual growth rate of 7.42% from the market size of US$601.070 million in 2022 to reach US$992.481 million in 2029.

The growth is attributed to the increasing demand for medical image archiving systems universalization, a reduction in data storage costs, and the high-level integration of the electronic health record industry. The vendor-neutral archive is also preferred due to its compatibility with older data archival systems.

The vendor-neutral archive (VNA) is a technology for medical imaging. The medical images and documents are archived in a proper standardized format with a standard interface. Due to the standardization, these images can be accessed in a vendor-neutral manner by any other system. The term is used in the traditional picture archiving and communication system.

The VNA and picture archiving and communicating systems share many common features. The VNA market is estimated to grow during the forecast period owing to the rising demand for storage based on standards, disaster recovery, lifecycle management strategies, and favorable government regulations for many top VNA companies.

Market Drivers:

  • The growing trend of electronic health records (EHR) is expected to propel the market.

At present, information-based decision-making is crucial for delivering quality care and maintaining efficient healthcare management. The availability of patients' health-related data is required for crucial decision-making. Although the data or patient information does exist in the various systems of numerous healthcare providers, it is not readily available to the doctor or clinician.

Most of the time, the patients' data is being floated in departmental silos and file systems. This will ultimately lead to decisions being taken based on incomplete information. In an attempt to prevent such situations or such decisions, the trend of electronic health records has been evolving. The vendor-neutral archive integrates the consolidation of patients' information with an electronic health record system. This allows doctors and clinicians to make effective decisions. The trend of electronic health records started long ago.

The initiatives taken by governments to enhance its outreach by undertaking various programs have accelerated its growth in both developed and developing countries worldwide. However, the EHR system is adopted more widely in developed countries owing to the early adoption of advanced technology. T Organizations with the high-level integration of electronic health records can liberate the patient's information and make it available to doctors or other healthcare professionals whenever required.

Picture archiving and communication systems, which have common features of VNA systems, are also expected to grow with the VNA market. Due to the rising awareness regarding VNA and picture archiving and communication systems, the adoption of these technologies has been done by many hospitals in developed countries, and a similar scope is expected in developing countries as well.

Other factors contributing to the VNA system's growth are the increasing focus on the healthcare sector and rising healthcare expenditures. The Vendor Neutral Archive is mostly used in radiology. It is also applied in ultrasound and MRI systems to record and store patient data.

Market Restraints:

  • The high cost of the system could hamper the market growth.

The vendor-neutral archive is avoided by consumers because this system does not provide long-term data. Similarly, this archive product does not stand alone with a short lifecycle. These factors create an obstacle in the path of the VNA market. Due to its high cost and doubts about its performance in storing large amounts of data, many developing countries have not implemented this technology in their hospitals.

North America holds a significant market share

North America has dominated the vendor-neutral archive market and is expected to continue its top position during the forecast period. North American countries, such as the United States and Canada, are the early adaptors of advanced technologies. These countries are at the frontline of reducing healthcare costs by applying various innovations.

Information systems are capable enough to reduce this cost and improve the outcomes. This system also improves the quality-of-care delivery. Considering these many advantages of the VNA system, North America is enhancing the development and usage of VNA in its countries. Thus, is expected to grow at a faster pace in the Vendor Neutral Archive market during the forecast period.

Key Developments:

  • March 2023- ConcertAI's TeraRecon partnered with Avicenna.AI to offer their CINA-iPE solution for detecting incidental pulmonary embolisms on their Eureka Clinical AI platform. The CE-marked AI tool analyzes CT scan images and detects embolisms with high accuracy. Avicenna.AI uses deep learning to identify and quantify life-threatening pathologies from CT images. TeraRecon's Eureka Clinical AI platform is the leading AI SaaS imaging interpretation and clinical decision augmentation solution, open to third-party AI algorithms. This global partnership aims to improve systematic reporting and treatment of life-threatening pulmonary emboli.
  • November 2022- Intelerad Medical Systems, a global leader in medical image management solutions, predicts a $76.8 billion cloud adoption by 2026 due to the COVID-19 pandemic and security concerns. Cloud technology offers comprehensive security measures, data redundancy, backup, and improved costs compared to on-premise solutions. Leading hospitals and health systems are focusing on cloud adoption for better access, improved medical data, and better enterprise imaging strategies. Intelerad's Cloud-Native Disaster Recovery solution provides secure, isolated, and immutable copies of patient imaging, while its Cloud Long-Term Archive ensures patient health information is safe and accessible.
  • April 2022- Fujifilm Healthcare Americas Corporation awarded a contract by the U.S. Department of Defense to standardize its digital imaging network's picture archiving and communication systems (DIN-PACS) in U.S. Naval and Air Force medical treatment facilities. The award was awarded through Fujifilm's 2017 DIN-PACS contract with the Defense Logistics Agency. The company has invested significantly in advancing its enterprise imaging portfolio to support critical healthcare environments. Synapse PACS, Fujifilm's next-generation server-side PACS system, enables secure imaging and reporting access beyond radiology departments and unifies imaging data across the enterprise.
  • March 2022-Philips introduced Ultrasound Workspace, a 2D/3D echocardiography solution that streamlines diagnostic workflows, improving diagnostic quality and productivity. The system features a user-friendly interface and AI-enabled image analysis tools, enabling faster quantitative measurements and improved inter-observer consistency. It also offers vendor-neutral application and data source capabilities. Philips has been instrumental in 3D echocardiography advancement, with software developed with input from physicians. The system offers an agile technology platform, flexible licensing for small- to large-scale organizations, and comprehensive application support.

Market Segmentation:

By Delivery Type

  • On-Premises VNA
  • Hybrid VNA
  • Fully Cloud-Hosted VNA

By Model

  • Departmental VNA
  • Multi-Departmental VNA
  • Multi-Site VNA

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL VENDOR NEUTRAL ARCHIVE (VNA) MARKET BY DELIVERY TYPE

  • 5.1. Introduction
  • 5.2. On-Premises VNA
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Hybrid VNA
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Fully Cloud-Hosted VNA
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness

6. GLOBAL VENDOR NEUTRAL ARCHIVE (VNA) MARKET BY MODEL

  • 6.1. Introduction
  • 6.2. Departmental VNA
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Multi-Departmental VNA
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Multi-Site VNA
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. GLOBAL VENDOR NEUTRAL ARCHIVE (VNA) MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Delivery Type
    • 7.2.2. By Model
    • 7.2.3. By Country
      • 7.2.3.1. USA
        • 7.2.3.1.1. Market Opportunities and Trends
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Opportunities and Trends
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Opportunities and Trends
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Delivery Type
    • 7.3.2. By Model
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Opportunities and Trends
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Opportunities and Trends
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Opportunities and Trends
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Delivery Type
    • 7.4.2. By Model
    • 7.4.3. By Country
      • 7.4.3.1. Germany
        • 7.4.3.1.1. Market Opportunities and Trends
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. France
        • 7.4.3.2.1. Market Opportunities and Trends
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. United Kingdom
        • 7.4.3.3.1. Market Opportunities and Trends
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. Italy
        • 7.4.3.4.1. Market Opportunities and Trends
        • 7.4.3.4.2. Growth Prospects
      • 7.4.3.5. Spain
        • 7.4.3.5.1. Market Opportunities and Trends
        • 7.4.3.5.2. Growth Prospects
      • 7.4.3.6. Others
        • 7.4.3.6.1. Market Opportunities and Trends
        • 7.4.3.6.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Delivery Type
    • 7.5.2. By Model
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
        • 7.5.3.1.1. Market Opportunities and Trends
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. UAE
        • 7.5.3.2.1. Market Opportunities and Trends
        • 7.5.3.2.2. Growth Prospects
        • 7.5.3.2.3.
      • 7.5.3.3. Others
        • 7.5.3.3.1. Market Opportunities and Trends
        • 7.5.3.3.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Delivery Type
    • 7.6.2. By Model
    • 7.6.3. By Country
      • 7.6.3.1. China
        • 7.6.3.1.1. Market Opportunities and Trends
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. Japan
        • 7.6.3.2.1. Market Opportunities and Trends
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. South Korea
        • 7.6.3.3.1. Market Opportunities and Trends
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. India
        • 7.6.3.4.1. Market Opportunities and Trends
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. Thailand
        • 7.6.3.5.1. Market Opportunities and Trends
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Taiwan
        • 7.6.3.6.1. Market Opportunities and Trends
        • 7.6.3.6.2. Growth Prospects
      • 7.6.3.7. Indonesia
        • 7.6.3.7.1. Market Opportunities and Trends
        • 7.6.3.7.2. Growth Prospects
      • 7.6.3.8. Others
        • 7.6.3.8.1. Market Opportunities and Trends
        • 7.6.3.8.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Afga healthcare
  • 9.2. FUJIFILM Holding Corporation
  • 9.3. Dell Technologies Inc
  • 9.4. GE Healthcare
  • 9.5. IBM Corporation
  • 9.6. Koninklijke Philips NV
  • 9.7. Lexmark International Inc
  • 9.8. McKesson Corporation
  • 9.9. Novarad Corporation
  • 9.10. Siemen AG
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦